These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2501 related items for PubMed ID: 24355409

  • 1. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [Abstract] [Full Text] [Related]

  • 2. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A.
    Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
    [Abstract] [Full Text] [Related]

  • 3. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins.
    Remon J, Morán T, Majem M, Reguart N, Dalmau E, Márquez-Medina D, Lianes P.
    Cancer Treat Rev; 2014 Feb; 40(1):93-101. PubMed ID: 23829935
    [Abstract] [Full Text] [Related]

  • 4. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K, Yuan Q.
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
    Uramoto H, Yamada T, Yano S, Kondo N, Hasegawa S, Tanaka F.
    Anticancer Res; 2012 Sep; 32(9):3785-90. PubMed ID: 22993320
    [Abstract] [Full Text] [Related]

  • 6. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
    Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, Yang SH, Lee SS, Kim CH, Yoo YD, Lee JC.
    Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
    [Abstract] [Full Text] [Related]

  • 7. MET and ALK as targets for the treatment of NSCLC.
    Capelletti M, Gelsomino F, Tiseo M.
    Curr Pharm Des; 2014 Oct; 20(24):3914-32. PubMed ID: 24138716
    [Abstract] [Full Text] [Related]

  • 8. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ, Shapiro GI.
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [Abstract] [Full Text] [Related]

  • 9. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
    Nurwidya F, Takahashi F, Murakami A, Kobayashi I, Kato M, Shukuya T, Tajima K, Shimada N, Takahashi K.
    Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
    [Abstract] [Full Text] [Related]

  • 10. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
    Zhou JY, Chen X, Zhao J, Bao Z, Chen X, Zhang P, Liu ZF, Zhou JY.
    Cancer Lett; 2014 Sep 01; 351(2):265-71. PubMed ID: 24983493
    [Abstract] [Full Text] [Related]

  • 11. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
    Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F.
    Clin Lung Cancer; 2014 May 01; 15(3):173-81. PubMed ID: 24486058
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D, Santini S, Cardinali B, Papoff G, Lalli C, Samperna S, Fustaino V, Giannini G, Ruberti G.
    PLoS One; 2015 May 01; 10(11):e0143333. PubMed ID: 26580964
    [Abstract] [Full Text] [Related]

  • 14. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
    Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S.
    Clin Cancer Res; 2010 Jan 01; 16(1):174-83. PubMed ID: 20008840
    [Abstract] [Full Text] [Related]

  • 15. MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer.
    Zhen Q, Liu J, Gao L, Liu J, Wang R, Chu W, Zhang Y, Tan G, Zhao X, Lv B.
    Cytogenet Genome Res; 2015 Jan 01; 146(1):1-8. PubMed ID: 26184032
    [Abstract] [Full Text] [Related]

  • 16. Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth.
    Jung SK, Lee MH, Lim DY, Lee SY, Jeong CH, Kim JE, Lim TG, Chen H, Bode AM, Lee HJ, Lee KW, Dong Z.
    Mol Carcinog; 2015 Apr 01; 54(4):322-31. PubMed ID: 24974831
    [Abstract] [Full Text] [Related]

  • 17. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
    Xie M, He CS, Wei SH, Zhang L.
    Eur J Cancer; 2013 Nov 01; 49(16):3559-72. PubMed ID: 23916913
    [Abstract] [Full Text] [Related]

  • 18. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.
    Clin Cancer Res; 2009 Feb 01; 15(3):907-13. PubMed ID: 19188161
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR, Zbuk K.
    Clin Ther; 2013 Sep 01; 35(9):1282-303. PubMed ID: 24054705
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 126.